WASHINGTON, Sept.14, 2015
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA)
today announced that it has named Richard
Gulino as Vanda's Senior Vice President, General Counsel and
Secretary. Mr. Gulino has over 20 years of strategic and
legal experience representing life sciences and healthcare
companies.
"I am very pleased to welcome Rick to the Vanda executive
management team," said Mihael H.
Polymeropoulos, M.D., President and CEO of Vanda. "He
is an exceptional leader and lawyer and brings a wealth of life
science experience that we expect will prove instrumental as we
continue to execute our global strategy."
Prior to joining Vanda, Mr. Gulino served as Vice President and
General Counsel of Ameritox, Ltd., a clinical drug testing
laboratory. Prior to this position, Mr. Gulino was Vice
President and Deputy General Counsel at Cephalon, Inc., a global
biopharmaceutical company specializing in discovering, developing
and marketing novel central nervous system, pain and oncology
medications, where he led the corporate/commercial legal
function.
Before joining Cephalon, Mr. Gulino served as a senior
commercial attorney at Zeneca, Inc. Mr. Gulino began his
legal career in private practice with Dow, Lohnes & Albertson
in Washington, DC. Mr.
Gulino received his Bachelor of Arts in history from Colgate University and his Juris Doctor with high
honors from Duke University School of
Law.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company
focused on the development and commercialization of products for
the treatment of central nervous system disorders. For more on
Vanda, please visit www.vandapharma.com.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release, including, without limitation,
statements regarding Vanda's global strategy, are "forward-looking
statements" under the securities laws. Forward-looking statements
are based upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Important factors
that could cause actual results to differ materially from those
reflected in Vanda's forward-looking are set forth in the "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Vanda's annual
report on Form 10-K for the fiscal year ended
December 31, 2014 and quarterly report on Form 10-Q for
the quarter ended June 30, 2015,
which are on file with the SEC and available on the SEC's website
at www.sec.gov. In addition to the risks described above and in
Vanda's annual report on Form 10-K and quarterly reports on
Form 10-Q, other unknown or unpredictable factors also could
affect Vanda's results. There can be no assurance that the actual
results or developments anticipated by Vanda will be realized or,
even if substantially realized, that they will have the expected
consequences to, or effects on, Vanda. Therefore, no assurance can
be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.
All written and verbal forward-looking statements attributable
to Vanda or any person acting on its behalf are expressly qualified
in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too
heavily on the forward-looking statements Vanda makes or that are
made on its behalf. The information in this release is provided
only as of the date of this release, and Vanda undertakes no
obligation, and specifically declines any obligation, to update or
revise publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Corporate Contact:
Jim
Kelly
Senior Vice President and Chief Financial
Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contact:
Laney Landsman
Assistant
Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-appointment-of-general-counsel-300141992.html
SOURCE Vanda Pharmaceuticals Inc.